Alzheimer's disease normative cerebrospinal fluid biomarkers validated in pet amyloid-β characterized subjects from the australian imaging, biomarkers and lifestyle (AIBL) study

QX Li; VL Villemagne; JD Doecke; A Rembach; S Sarros; S Varghese; A McGlade; KM Laughton; KK Pertile; CJ Fowler; RL Rumble; BO Trounson; K Taddei; SR Rainey-Smith; SM Laws; JS Robertson; LA Evered; B Silbert; KA Ellis; CC Rowe; SL Macaulay; D Darby; RN Martins; D Ames; CL Masters; S Collins

Journal article

Alzheimer's disease normative cerebrospinal fluid biomarkers validated in pet amyloid-β characterized subjects from the australian imaging, biomarkers and lifestyle (AIBL) study

QX Li, VL Villemagne, JD Doecke, A Rembach, S Sarros, S Varghese, A McGlade, KM Laughton, KK Pertile, CJ Fowler, RL Rumble, BO Trounson, K Taddei, SR Rainey-Smith, SM Laws, JS Robertson, LA Evered, B Silbert, KA Ellis, CC Rowe Show all

Journal of Alzheimer S Disease | Published : 2015

DOI: 10.3233/JAD-150247

Abstract

Background: The cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42, total-tau (T-tau), and phosphorylated-tau (P-tau181P) profile has been established as a valuable biomarker for Alzheimer's disease (AD). Objective: The current study aimed to determine CSF biomarker cut-points using positron emission tomography (PET) Aβ imaging screened subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, as well as correlate CSF analyte cut-points across a range of PET Aβ amyloid ligands. Methods: Aβ pathology was determined by PET imaging, utilizing 11C-Pittsburgh Compound B, 18F-flutemetamol, or 18Fflorbetapir, in 157 AIBL participants who also underwent CSF collection. Using an..

View full abstract

University of Melbourne Researchers

Qiao-Xin Li Author

Victor Villemagne Author

Lis Evered Author

Brendan Silbert Author

Related Projects (2)

DETERMINING NORMAL PRION PROTEIN FUNCTION, EMPHASISING THE ROLE PLAYED BY PROTEIN CLEAVAGE, AND ALSO DEFINING THE RELATIONSHIP BETWEEN SURVEILLANCE INTENSITY AND ANNUAL SPORADIC CJD INCIDENCE

As a neurologist undertaking research into prion diseases over an extended period, I have been able to lead and participate in many projects..

MOLECULAR IMAGING OF NEURODEGENERATION

This research proposal outlines studies aimed at identifying specific biomarkers of neurodegeneration. Given the complexity and clinical ove..

Grants

Awarded by National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program

Awarded by NHMRC

Funding Acknowledgements

Core funding for the study was provided by the Science and Industry Endowment Fund (http://www.sief.org.au) and CSIRO, which was supplemented by "in kind" contributions from the study partners (see www.aibl.csiro.au). The research was also supported by the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2). The Mental Health Research Institute acknowledges the funding support from the Victorian government's Operational Infrastructure Support program. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study. VL Villemagne is supported by NHMRC Research Fellowship (#APP1046471). S Collins is supported in part by an NHMRC Practitioner Fellowship (#APP1005816).